Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by francois21on Dec 15, 2015 8:13pm
587 Views
Post# 24386796

RE:New membre from Cambridge University Staff

RE:New membre from Cambridge University Staff
Edmodo wrote: I’m from London UK
 
Fisrt time on Stockhouse
I read your posts from time to time when it’s raining cats and dogs here!
I followed the Promatic company for the last 6 months or so.
I discovered them on a Formation/resin selling platform webcast here
I will probably invest on that stock in the weeks to come.
Knowing from you that all the Board of Directors where here London last week I started to ask myself who there had meeting with?
They are obviously negotiating a join venture!   
There is my short list.
 
1.     Smith & Nephew Wound Care in London
2.    G.E. Health Care life science in Little Chaltfont
3.    AstraZeneca Small Molecules in London
4.    Karus Therapeutics Hampshire
5.    GlaxoSmithKline Barnard Castle
 
All these companies would have a good strategic reason to do a join venture deal with Promatic
ANY COMMENTS?

Ed Modo.


1. I don't know them, they have a branch for wound management, but they don't seems to me to be the ideal partners for plasminogen treatment. PLI will need a much bigger pharma as a partner in my view. 

2. After surfing GE Healthcare life science section, they don't seems to have a pipeline of products, but they have a large section of purification and bioseperation solution. However, we don't hear their name to often, contrary to CSL, Octopharma, Baxter. They could need a push with the PPPS solution. They have installation around the world, they could be a nice partner for PPPS rights for specific proteins in a specific area. 

3.Astra Zeneca have a huge pipeline. They have a focus on repiratory and metabolic disease. PBI-4050 could fit for either IPF or diabet, but also AAT could fit with them for the teatment of COPD.

4. Karus Therapeutics is another company that I don't know about them. However, looking at their pipeline, they have a few products for cancer therapy in the pipeline, all in preclinical, and are an early stage company that probably is burning a lot of cash and have no revenues. I can't see at this point how they could be a partner for PLI.


5.GSK. Well, I will make it simple for this company: They are in everything, everywhere.... So anything PLI have, can fit them!

Just my opinion for the fun of it.  

Bullboard Posts